Reduced Mother-to-Baby Transmission Leads to Dicontinuation of HIV Trial
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Reduced Mother-to-Baby Transmission Leads to Dicontinuation of HIV Trial

BOCA RATON, Fla., March 26, 1997 -- An unexpectedly low rate of infant infection has led the Data Safety Monitoring Board (DSMB) to recommend that the National Institutes of Health (NIH) discontinue patient enrollment in its Phase III clinical trial of HIV-IG(TM). The decision was made in light of the fact that current therapy using AZT has reduced the rate of mother to baby HIV transmission so low that it is not feasible to show statistically significant efficacy for a combination of AZT and HIV-IG(TM).

There were no safety issues pertaining to HIV-IG.

The makers of HIV-IG plan to continue a Phase II dosing study to test the product's safety and efficacy in the treatment of HIV-infected children. The NIH-sponsored pediatric study of HIV-IG is fully enrolled, and completion is expected during 1997.

NABI, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of products that prevent and treat autoimmune and infectious diseases.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities